-
2
-
-
0028177035
-
-
(a) Abraham W.M., Sielczak M.W., Ahmed A., Cortes A., Lauredo I.T., Kim J., Pepinsky B., Benjamin C.D., Leone D.R., Lobb R.R., Weller P.F. J. Clin. Invest. 93:1994;776 (b) Milne A.A.Y., Piper P.J. Eur. J. Pharmacol. 282:1995;243.
-
(1994)
J. Clin. Invest.
, vol.93
, pp. 776
-
-
Abraham, W.M.1
Sielczak, M.W.2
Ahmed, A.3
Cortes, A.4
Lauredo, I.T.5
Kim, J.6
Pepinsky, B.7
Benjamin, C.D.8
Leone, D.R.9
Lobb, R.R.10
Weller, P.F.11
-
3
-
-
0029091551
-
-
(a) Abraham W.M., Sielczak M.W., Ahmed A., Cortes A., Lauredo I.T., Kim J., Pepinsky B., Benjamin C.D., Leone D.R., Lobb R.R., Weller P.F. J. Clin. Invest. 93:1994;776 (b) Milne A.A.Y., Piper P.J. Eur. J. Pharmacol. 282:1995;243.
-
(1995)
Eur. J. Pharmacol.
, vol.282
, pp. 243
-
-
Milne, A.A.Y.1
Piper, P.J.2
-
4
-
-
0026506799
-
-
(a) Yednock T.A., Cannon D., Fritz L.C. Nature. 356:1992;63 (b) Kesztheylyi E., Karlik S., Hyduk S., Rice A., Gordon G., Yednock T., Horner H. Neurology. 47:1996;1053.
-
(1992)
Nature
, vol.356
, pp. 63
-
-
Yednock, T.A.1
Cannon, D.2
Fritz, L.C.3
-
5
-
-
0029834867
-
-
(a) Yednock T.A., Cannon D., Fritz L.C. Nature. 356:1992;63 (b) Kesztheylyi E., Karlik S., Hyduk S., Rice A., Gordon G., Yednock T., Horner H. Neurology. 47:1996;1053.
-
(1996)
Neurology
, vol.47
, pp. 1053
-
-
Kesztheylyi, E.1
Karlik, S.2
Hyduk, S.3
Rice, A.4
Gordon, G.5
Yednock, T.6
Horner, H.7
-
7
-
-
0027248939
-
-
Podolsky D.K., Lobb R., King N., Benjamin C.D., Pepinsky B., Sehgal P., DeBaumont M. J. Clin. Invest. 92:1993;372.
-
(1993)
J. Clin. Invest.
, vol.92
, pp. 372
-
-
Podolsky, D.K.1
Lobb, R.2
King, N.3
Benjamin, C.D.4
Pepinsky, B.5
Sehgal, P.6
DeBaumont, M.7
-
8
-
-
85031075157
-
-
Natalizumab, Biogen, Inc, Press Release 2002, April 29, Reference number RF449588.
-
Natalizumab, Biogen, Inc, Press Release 2002, April 29, Reference number RF449588.
-
-
-
-
9
-
-
85031071026
-
-
SB-683698, GlaxoSmithKline plc, Company Brochure 2001, February 22, Reference number RF399771.
-
(a) SB-683698, GlaxoSmithKline plc, Company Brochure 2001, February 22, Reference number RF399771. (b) GW-559090, GlaxoSmithKline plc, Company Publication 2001, October 23, Reference number RF426830. (c) IVL-745 and IVL-1031, Aventis Pharma AG, Company Presentation 2001, May 15, Reference number RF409257. (d) R-411, Hoffmann-La Roche Inc, Company Presentation 2002, April 16, Reference number RF448015.
-
-
-
-
10
-
-
85031076092
-
-
GW-559090, GlaxoSmithKline plc, Company Publication 2001, October 23, Reference number RF426830.
-
(a) SB-683698, GlaxoSmithKline plc, Company Brochure 2001, February 22, Reference number RF399771. (b) GW-559090, GlaxoSmithKline plc, Company Publication 2001, October 23, Reference number RF426830. (c) IVL-745 and IVL-1031, Aventis Pharma AG, Company Presentation 2001, May 15, Reference number RF409257. (d) R-411, Hoffmann-La Roche Inc, Company Presentation 2002, April 16, Reference number RF448015.
-
-
-
-
11
-
-
85031068446
-
-
IVL-745 and IVL-1031, Aventis Pharma AG, Company Presentation 2001, May 15, Reference number RF409257.
-
(a) SB-683698, GlaxoSmithKline plc, Company Brochure 2001, February 22, Reference number RF399771. (b) GW-559090, GlaxoSmithKline plc, Company Publication 2001, October 23, Reference number RF426830. (c) IVL-745 and IVL-1031, Aventis Pharma AG, Company Presentation 2001, May 15, Reference number RF409257. (d) R-411, Hoffmann-La Roche Inc, Company Presentation 2002, April 16, Reference number RF448015.
-
-
-
-
12
-
-
85031075255
-
-
R-411, Hoffmann-La Roche Inc, Company Presentation 2002, April 16, Reference number RF448015.
-
(a) SB-683698, GlaxoSmithKline plc, Company Brochure 2001, February 22, Reference number RF399771. (b) GW-559090, GlaxoSmithKline plc, Company Publication 2001, October 23, Reference number RF426830. (c) IVL-745 and IVL-1031, Aventis Pharma AG, Company Presentation 2001, May 15, Reference number RF409257. (d) R-411, Hoffmann-La Roche Inc, Company Presentation 2002, April 16, Reference number RF448015.
-
-
-
-
13
-
-
85031083223
-
-
Boston, Aug 20-24, 2000; American Chemical Society: Washington, DC, 2000; MEDI 140.
-
(a) Chen, Q.; Li, j.; Maxwell, D.; Holland, G.; Dixon, R.; You, T. 220th National Meeting of the American Chemical Society, Boston, Aug 20-24, 2000; American Chemical Society: Washington, DC, 2000; MEDI 140. (b) Singh, J.; Zheng, Z.; Sprague, P.; Van Vilhemen, H.; Castro, A.C.; Adams, S.P. WO 9804913. (c) Singh J., Vlijmen H.V., Liao Y., Lee W., Mark C., Harris M., Shu I., Gill A., Cuervo J., Abraham W.M., Adams S. P. J. Med. Chem. 45:2002;2988.
-
220th National Meeting of the American Chemical Society
-
-
Chen, Q.1
Li, J.2
Maxwell, D.3
Holland, G.4
Dixon, R.5
You, T.6
-
14
-
-
85031067107
-
-
S.P. WO 9804913.
-
(a) Chen, Q.; Li, j.; Maxwell, D.; Holland, G.; Dixon, R.; You, T. 220th National Meeting of the American Chemical Society, Boston, Aug 20-24, 2000; American Chemical Society: Washington, DC, 2000; MEDI 140. (b) Singh, J.; Zheng, Z.; Sprague, P.; Van Vilhemen, H.; Castro, A.C.; Adams, S.P. WO 9804913. (c) Singh J., Vlijmen H.V., Liao Y., Lee W., Mark C., Harris M., Shu I., Gill A., Cuervo J., Abraham W.M., Adams S. P. J. Med. Chem. 45:2002;2988.
-
-
-
Singh, J.1
Zheng, Z.2
Sprague, P.3
Van Vilhemen, H.4
Castro, A.C.5
Adams6
-
15
-
-
0037019269
-
-
(a) Chen, Q.; Li, j.; Maxwell, D.; Holland, G.; Dixon, R.; You, T. 220th National Meeting of the American Chemical Society, Boston, Aug 20-24, 2000; American Chemical Society: Washington, DC, 2000; MEDI 140. (b) Singh, J.; Zheng, Z.; Sprague, P.; Van Vilhemen, H.; Castro, A.C.; Adams, S.P. WO 9804913. (c) Singh J., Vlijmen H.V., Liao Y., Lee W., Mark C., Harris M., Shu I., Gill A., Cuervo J., Abraham W.M., Adams S. P. J. Med. Chem. 45:2002;2988.
-
(2002)
P. J. Med. Chem.
, vol.45
, pp. 2988
-
-
Singh, J.1
Vlijmen, H.V.2
Liao, Y.3
Lee, W.4
Mark, C.5
Harris, M.6
Shu, I.7
Gill, A.8
Cuervo, J.9
Abraham, W.M.10
Adams, S.11
-
19
-
-
0037013435
-
-
Doherty G.A., Yang G.X., Chang L.L., MacCoss M., Tong S., Kidambi U., Egger L.A., McCauly E., Riper G.V., Mumford R.A., Schmidt J.A., Hagmann W.K. Bioorg. Med. Chem. 12:2002;1501.
-
(2002)
Bioorg. Med. Chem.
, vol.12
, pp. 1501
-
-
Doherty, G.A.1
Yang, G.X.2
Chang, L.L.3
MacCoss, M.4
Tong, S.5
Kidambi, U.6
Egger, L.A.7
McCauly, E.8
Riper, G.V.9
Mumford, R.A.10
Schmidt, J.A.11
Hagmann, W.K.12
-
20
-
-
85031081070
-
-
SYBYL 6.8, Tripos Inc.: 1669, S. Hanley Road, Suite 303, St. Louis, MO 63144-2913, USA.
-
SYBYL 6.8, Tripos Inc.: 1669, S. Hanley Road, Suite 303, St. Louis, MO 63144-2913, USA.
-
-
-
-
21
-
-
0037168051
-
-
Desiraju G.R., Gopalakrishnan B., Jetti R.K.R., Nagaraju A., Raveendra D., Sarma J.A.R.P., Sobhia M.E., Thilagavathi R. J. Med. Chem. 22:2002;4847.
-
(2002)
J. Med. Chem.
, vol.22
, pp. 4847
-
-
Desiraju, G.R.1
Gopalakrishnan, B.2
Jetti, R.K.R.3
Nagaraju, A.4
Raveendra, D.5
Sarma, J.A.R.P.6
Sobhia, M.E.7
Thilagavathi, R.8
-
25
-
-
85031083896
-
-
San Diego, CA, Sept 27-30, 2002; American Society for Microbiology: Washington, DC, 2002.
-
Gopalakrishnan, B., Khandelwal, A., Rajjak, S.A., Selvakumar, N., Das, J., Trehan, S., Iqbal, J., Sitaram Kumar, M., Rajagopalan, R. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, Sept 27-30, 2002; American Society for Microbiology: Washington, DC, 2002.
-
42nd Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Gopalakrishnan, B.1
Khandelwal, A.2
Rajjak, S.A.3
Selvakumar, N.4
Das, J.5
Trehan, S.6
Iqbal, J.7
Sitaram Kumar, M.8
Rajagopalan, R.9
|